123 related articles for article (PubMed ID: 36727271)
1. Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer.
Hamai K; Miyaka S; Tada S; Fujita S; Hirakawa T; Matsumura M; Ueno S; Tanimoto T; Ishikawa N
Cancer Rep (Hoboken); 2023 Apr; 6(4):e1793. PubMed ID: 36727271
[TBL] [Abstract][Full Text] [Related]
2. [Efforts to Reduce the Risk of Febrile Neutropenia and to Increase the Response Rate to Docetaxel and Ramucirumab Therapy in Patients with Non-Small Cell Lung Cancer].
Yamamoto A; Iwata T
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1421-1425. PubMed ID: 31530782
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan.
Kondo Y; Tachi T; Sakakibara T; Kato J; Kato A; Mizuno T; Miyake Y; Teramachi H
Support Care Cancer; 2022 Aug; 30(8):6775-6783. PubMed ID: 35524869
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051.
Miura K; Yamaguchi O; Mori K; Nakamura A; Tamiya M; Oba T; Yanagitani N; Mizutani H; Ninomiya T; Kajiwara T; Ito K; Miyanaga A; Arai D; Kodama H; Kobayashi K; Kaira K
Sci Rep; 2024 Feb; 14(1):3816. PubMed ID: 38360906
[TBL] [Abstract][Full Text] [Related]
5. Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study.
Kasahara N; Sunaga N; Kuwako T; Naruse I; Imai H; Jingu A; Tsukagoshi Y; Masuda T; Kitahara S; Tsurumaki H; Yatomi M; Hara K; Koga Y; Sakurai R; Mori K; Kaira K; Maeno T; Asao T; Hisada T
Support Care Cancer; 2020 Oct; 28(10):4825-4831. PubMed ID: 31982960
[TBL] [Abstract][Full Text] [Related]
6. Investigation of response of patients with non-small cell lung cancer to docetaxel (plus ramucirumab) therapy in second-line treatment.
Takahara Y; Abe R; Nagae S; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Nishiki K; Nojiri M; Kato R; Shinomiya S; Oikawa T
Thorac Cancer; 2023 Dec; 14(36):3549-3555. PubMed ID: 37964501
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Onoi K; Yamada T; Morimoto K; Kawachi H; Tsutsumi R; Takeda T; Okada A; Tamiya N; Chihara Y; Shiotsu S; Takemura Y; Yamada T; Hasegawa I; Katayama Y; Iwasaku M; Tokuda S; Takayama K
Target Oncol; 2024 May; 19(3):411-421. PubMed ID: 38467958
[TBL] [Abstract][Full Text] [Related]
8. Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer.
Matsui A; Morise M; Tanaka I; Ozone S; Matsuzawa R; Koyama J; Hase T; Hashimoto N; Sato M; Hasegawa Y
Cancer Invest; 2020 Aug; 38(7):424-430. PubMed ID: 32643445
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
Hata A; Katakami N; Shimokawa M; Mitsudomi T; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2018 Nov; 19(6):e865-e869. PubMed ID: 30206044
[TBL] [Abstract][Full Text] [Related]
10. Influence of using history of immune checkpoint inhibitor therapy for neutropenia caused by combination therapy of ramucirumab and docetaxel.
Ohno H; Mano S; Katagiri N; Oguri R; Miyazaki K; Ito K; Sekiya Y; Inoue K; Masuda A; Tsuzuku A; Asano F; Hirashita T; Hayashi T
Pharmazie; 2022 Sep; 77(7):248-254. PubMed ID: 36199179
[TBL] [Abstract][Full Text] [Related]
11. Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment.
Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Ariyasu R; Uchibori K; Yanagitani N; Horai T; Seike M; Gemma A; Nishio M
Lung Cancer; 2020 Jun; 144():71-75. PubMed ID: 32387683
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
[TBL] [Abstract][Full Text] [Related]
13. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of Primary Prophylaxis with Pegfilgrastim after Docetaxel for Castration-Resistant Prostate Cancer].
Koutake Y; Tsurusaki Y; Fujita T; Inoue D; Hanada K; Nakagawa Y
Gan To Kagaku Ryoho; 2019 Nov; 46(11):1721-1725. PubMed ID: 31748481
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of primary prophylaxis of febrile neutropenia with pegfilgrastim in docetaxel, cisplatin and 5-fluorouracil therapy for esophageal cancer.
Ichimura T; Nomura H; Shimizu H; Machida Y; Suzuki K
Pharmazie; 2021 Sep; 76(9):450-454. PubMed ID: 34481537
[No Abstract] [Full Text] [Related]
16. Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer.
Ichinose I; Hamada Y; Mitsuyama S; Ishikawa E; Ikeda T; Kobayashi S; Horikoshi N; Tamura K
Chemotherapy; 2008; 54(5):379-85. PubMed ID: 18758179
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
[TBL] [Abstract][Full Text] [Related]
18. Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.
Ishikawa T; Yasuda T; Okayama T; Dohi O; Yoshida N; Kamada K; Uchiyama K; Takagi T; Konishi H; Shiozaki A; Fujiwara H; Konishi H; Naito Y; Teramukai S; Itoh Y
Cancer Sci; 2019 Dec; 110(12):3754-3760. PubMed ID: 31646714
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.
Hata A; Harada D; Okuda C; Kaji R; Masuda Y; Takechi Y; Kozuki T; Nogami N; Katakami N
Oncotarget; 2018 Jun; 9(45):27789-27796. PubMed ID: 29963237
[TBL] [Abstract][Full Text] [Related]
20. [Measures to Ensure Safety of Docetaxel plus Ramucirumab for Advanced Non-Small-Cell Lung Cancer as the Second- or Later-Line].
Takase M; Shibata K; Iwasa K; Shimizu M; Fujii Y; Takahashi M
Gan To Kagaku Ryoho; 2019 Jun; 46(6):1039-1042. PubMed ID: 31273171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
